Information  X 
Enter a valid email address

Verseon Corp COM USD0.001 (DI) (VSN)

Date Time Source Announcement
18 Sep 2018 7:00 am
RNS
Verseon unveils new blockchain technology
13 Sep 2018 7:00 am
RNS
Verseon commences anticoagulant phase I trial
31 Aug 2018 7:00 am
RNS
Additional Listing & Total Voting Rights
16 Aug 2018 7:00 am
RNS
Change of Adviser
08 Aug 2018 7:00 am
RNS
Interim Results
18 Jul 2018 7:00 am
RNS
Verseon submits phase I protocol for VE-1902
06 Jul 2018 7:00 am
RNS
Additional Listing & Total Voting Rights
02 Jul 2018 7:00 am
RNS
Additional Listing & Total Voting Rights
25 Jun 2018 7:00 am
RNS
Final Results
14 Jun 2018 7:00 am
RNS
Verseon preparing for anticoagulant phase I trial
13 Jun 2018 7:03 am
RNS
Verseon closes US$ 22.7M mortgage
12 Jun 2018 7:00 am
RNS
Additional Listing & Total Voting Rights
07 Jun 2018 7:00 am
RNS
Verseon presents anticoagulants at BIO 2018
02 May 2018 7:00 am
RNS
Verseon presents DME efficacy data at ARVO 2018
18 Apr 2018 7:00 am
RNS
Verseon presents anticancer agents at AACR 2018
03 Apr 2018 7:00 am
RNS
Additional Listing & Total Voting Rights
05 Mar 2018 7:00 am
RNS
Additional Listing & Total Voting Rights
10 Jan 2018 7:00 am
RNS
Verseon presents HAE program at Biotech Showcase
02 Jan 2018 7:00 am
RNS
Additional Listing & Total Voting Rights
15 Nov 2017 7:00 am
RNS
Verseon presents second anticoagulant candidate
14 Nov 2017 7:00 am
RNS
Additional Listing & Total Voting Rights
08 Nov 2017 7:00 am
RNS
Verseon presents anticancer agents at BIO-Europe
  7:00 am
RNS
Additional Listing & Total Voting Rights
20 Oct 2017 7:00 am
RNS
Result of Special Meeting & Board Appointment
02 Oct 2017 7:00 am
RNS
Verseon presents new DME efficacy results
25 Sep 2017 7:00 am
RNS
Special Shareholder Meeting & Change of Directors
  7:00 am
RNS
Interim Results
22 Sep 2017 7:00 am
RNS
Verseon closes PACE financing for its new facility
07 Aug 2017 7:00 am
RNS
Additional Listing and Total Voting Rights
26 Jun 2017 7:00 am
RNS
Verseon presents data on DME program at BIO 2017
12 Jun 2017 7:00 am
RNS
Verseon to present drug programs at BIO 2017
06 Jun 2017 8:15 am
RNS
Transaction in Own Shares and Total Voting Rights
02 May 2017 7:00 am
RNS
Additional Listing & Total Voting Rights
26 Apr 2017 7:00 am
RNS
TR-1 Notification of Major Interest in Shares
  7:00 am
RNS
Result of 2017 Annual General Meeting
03 Apr 2017 7:00 am
RNS
Announcement of 2017 Annual General Meeting
30 Mar 2017 7:00 am
RNS
Verseon to present anticoagulants at ACS 2017
20 Mar 2017 7:00 am
RNS
BIO-Europe Spring: Verseon presents anticoagulants
13 Mar 2017 7:00 am
RNS
Final Results
30 Jan 2017 7:00 am
RNS
Additional Listing & Total Voting Rights
04 Jan 2017 7:00 am
RNS
Verseon granted US patents for its inhibitors
06 Dec 2016 7:00 am
RNS
Lower bleeding risk of Verseon anticoagulants
23 Nov 2016 7:03 am
RNS
Verseon anticoagulants preserve platelet function
16 Nov 2016 7:00 am
RNS
Additional Listing & Total Voting Rights
14 Nov 2016 7:00 am
RNS
New anticoagulant data to be presented at AHA 2016
07 Nov 2016 7:00 am
RNS
Appointment of Corporate Brokers
31 Oct 2016 7:00 am
RNS
Additional Listing & Total Voting Rights
27 Oct 2016 8:41 am
RNS
Additional Listing & Total Voting Rights
21 Sep 2016 7:00 am
RNS
Director/PDMR Shareholding
12 Sep 2016 7:00 am
RNS
Additional Listing & Total Voting Rights
08 Sep 2016 7:00 am
RNS
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
05 Sep 2016 7:00 am
RNS
Interim Results
09 Aug 2016 11:40 am
RNS
Additional Listing & Total Voting Rights
22 Jun 2016 7:00 am
RNS
Additional Listing & Total Voting Rights
06 Jun 2016 7:00 am
RNS
Verseon to Present Latest Anticoagulant Results
27 Apr 2016 7:00 am
RNS
Additional Listing & Total Voting Rights
21 Apr 2016 7:00 am
RNS
Result of AGM
07 Apr 2016 7:00 am
RNS
Notice of AGM
06 Apr 2016 7:00 am
RNS
TR-1: Notification of Major Interest in Shares
04 Apr 2016 7:00 am
RNS
Verseon to present additional results at BioEurope
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t